Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Hemab Therapeutics Holdings, Inc. (COAG)

Hemab Therapeutics Q1 net loss widens to $22.7 million as IPO closes in May

Negative Impact 3 of 5 earnings Written later

Hemab Therapeutics reported a first quarter 2026 net loss of $22.7 million, or $23.98 per share, up from $15.3 million, or $16.18 per share, a year earlier, as research and development spending rose. The company completed an upsized IPO in May 2026 at $18.00 per share, raising gross proceeds of $346.7 million, and says its cash and the expected net proceeds of about $317.2 million will fund operations into 2029.

Key points

  • Q1 2026 net loss was $22.7 million, or $23.98 per share, versus $15.3 million, or $16.18 per share, in Q1 2025
  • Research and development expenses rose to $19.5 million from $14.1 million; general and administrative expenses rose to $4.2 million from $2.5 million
  • Cash, cash equivalents and marketable securities were $163.5 million at March 31, 2026, down from $185.5 million at December 31, 2025
  • IPO of 19,262,500 shares at $18.00 per share raised gross proceeds of $346.7 million; common stock began trading on Nasdaq as COAG

The filing

CompanyHemab Therapeutics Holdings, Inc. (COAG)
Form8-K, current report
Filed with the SECMay 21, 2026, 7:05 AM ET
Accession number0001193125-26-233375

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.